We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Web Microsite Introduces Single Cell Gene Expression Profiling

By LabMedica International staff writers
Posted on 22 Dec 2009
A Web microsite introduces the rapidly expanding field of single cell gene expression profiling.

Historically, gene expression profiling of single cells, such as stem cells, circulating tumor and formalin-fixed, paraffin-embedded (FFPE) tissues has been difficult and expensive to perform. More...
Now, however, results from single-cell samples can be obtained easily and inexpensively using the Fluidigm Corp's (South San Francisco, CA, USA) BioMark system and the company's Dynamic Array integrated fluidic circuits (IFCs). Dynamic Array IFCs are ideally suited for high-throughput cell-line studies to determine individual cell behavior in a homozygous population.

Visitors to Fluidigm Web site (see below) can gain an understanding of the technology, find out how international scientists using Fluidigm Dynamic Array chips are accelerating their research, and evaluate whether IFC technology is suitable for their project.

A five-minute audiovisual presentation provides an informative introduction to how IFC technology is now providing a practical means of studying single cells A wide selection of downloadable customer conference posters, peer-reviewed publications, success stories and application notes describe the technology in action and the benefits it is delivering to leading laboratories around the world.

Fluidigm develops, manufactures, and markets proprietary IFC systems that improve productivity in life-science research. Fluidigm's IFCs enable the simultaneous performance of thousands of sophisticated biochemical measurements in extremely minute volumes. These "integrated circuits for biology” are made possible by miniaturizing and integrating liquid-handling components on a single microfabricated microfluidic device. Fluidigm's IFC systems, consisting of instrumentation, software, and single-use IFCs, increase throughput, decrease costs, and enhance sensitivity compared to conventional laboratory systems. Fluidigm products have not been cleared or approved by the U.S. Food and Drug Administration (FDA) for use as a diagnostic and are only available for research use.

Related Links:
Fluidigm single cell analysis presentation
Fluidigm



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.